18.98
price up icon3.66%   0.67
after-market Handel nachbörslich: 19.00 0.02 +0.11%
loading
Schlusskurs vom Vortag:
$18.31
Offen:
$18.36
24-Stunden-Volumen:
1.39M
Relative Volume:
0.28
Marktkapitalisierung:
$14.00B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-196.68M
KGV:
-11.29
EPS:
-1.6811
Netto-Cashflow:
$-113.02M
1W Leistung:
-12.82%
1M Leistung:
-10.51%
6M Leistung:
+327.48%
1J Leistung:
+883.42%
1-Tages-Spanne:
Value
$18.11
$19.25
1-Wochen-Bereich:
Value
$18.11
$22.25
52-Wochen-Spanne:
Value
$1.89
$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Firmenname
Summit Therapeutics Inc
Name
Telefon
305-203-2034
Name
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Name
Mitarbeiter
105
Name
Twitter
@summitplc
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
SMMT's Discussions on Twitter

Vergleichen Sie SMMT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
SMMT 18.98 14.00B 956.00K -196.68M -113.02M -1.6811
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2018-06-28 Herabstufung Janney Buy → Neutral
2018-05-02 Eingeleitet Janney Buy
2018-04-12 Bestätigt Needham Buy
2018-02-13 Eingeleitet BTIG Research Buy
2018-01-04 Eingeleitet SunTrust Buy
2017-12-01 Fortgesetzt H.C. Wainwright Buy
2016-11-16 Bestätigt RBC Capital Mkts Outperform
2016-10-05 Bestätigt Needham Buy
2016-09-16 Eingeleitet H.C. Wainwright Buy
2015-03-30 Eingeleitet Needham Buy
2015-03-30 Eingeleitet Oppenheimer Outperform
Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

pulisher
08:32 AM

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

08:32 AM
pulisher
Nov 17, 2024

(SMMT) Trading Report - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

Here's Merck's $3.3 Billion Insurance Against Summit's Advance - Investor's Business Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters

Nov 14, 2024
pulisher
Nov 13, 2024

Has Summit Therapeutics Stock Already Peaked? - AOL

Nov 13, 2024
pulisher
Nov 12, 2024

2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL

Nov 12, 2024
pulisher
Nov 11, 2024

2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL

Nov 11, 2024
pulisher
Nov 09, 2024

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga

Nov 09, 2024
pulisher
Nov 09, 2024

Is Summit Therapeutics a Millionaire Maker? - AOL

Nov 09, 2024
pulisher
Nov 08, 2024

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Why Summit Therapeutics Stock Was a Winner Today - MSN

Nov 08, 2024
pulisher
Nov 06, 2024

Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 04, 2024

SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics Leads The Parade Of Big Gainers - Forbes

Nov 04, 2024
pulisher
Nov 04, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN

Nov 04, 2024
pulisher
Nov 03, 2024

3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool

Nov 03, 2024
pulisher
Nov 01, 2024

abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics (NASDAQ:SMMT) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics reports Q3 EPS (5c), consensus (7c) - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Summit Therapeutics Advances NSCLC Trials and Strengthens Financials - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 10.4%What's Next? - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - BioSpace

Oct 30, 2024
pulisher
Oct 29, 2024

China Universal Asset Management Co. Ltd. Purchases 56,879 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Tesla, Xpeng, Summit Therapeutics lead Monday's morning market cap stock movers - Investing.com Australia

Oct 28, 2024
pulisher
Oct 28, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan

Oct 28, 2024
pulisher
Oct 27, 2024

Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer - Insider Monkey

Oct 27, 2024
pulisher
Oct 27, 2024

Billionaire Buys Miami Penthouse After His Firm’s 689% Stock Rally - MSN

Oct 27, 2024
pulisher
Oct 27, 2024

8 Unstoppable Stocks That Could Make You Richer - Insider Monkey

Oct 27, 2024
pulisher
Oct 25, 2024

Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings? - MSN

Oct 25, 2024

Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):